|
Subgroup
|
No. of Studies
|
No. of Patients
|
Random-Effects Model RR (95% CI)
|
Test for Effect P
|
I2(%)
|
Test for Heterogeneity P
|
Meta regression P
|
|---|
|
All Studies
|
9
|
1636
|
0.98 (0.78, 1.23)
|
0.84
|
60
|
0.01
| |
|
Study Design
| | | | | | |
0.216
|
|
Single-center
|
4
|
511
|
0.58 (0.25, 1.36)
|
0.21
|
78
|
0.003
| |
|
Multicenter
|
5
|
1125
|
1.03 (0.91, 1.17)
|
0.61
|
0
|
0.75
| |
|
Sample Size
| | | | | | |
0.362
|
|
< 100
|
3
|
148
|
0.37 (0.07, 1.90)
|
0.23
|
82
|
0.004
| |
|
≥ 100
|
6
|
1488
|
1.00 (0.83, 1.21)
|
0.98
|
44
|
0.11
| |
|
Patient Population
| | | | | | | |
|
Multisystem
|
6
|
1340
|
1.00 (0.82, 1.22)
|
0.99
|
42
|
0.120
| |
|
Post cardiac surgery
|
3
|
296
|
0.37 (0.07, 1.81)
|
0.22
|
83
|
0.003
| |
|
RRT Modality
| | | | | | |
0.838
|
|
CVVH
|
5
|
665
|
0.91 (0.63, 1.32)
|
0.62
|
71
|
0.007
| |
|
IHD
|
2
|
252
|
0.63 (0.06, 6.19)
|
0.69
|
79
|
0.03
| |
|
CVVH/IHD
|
2
|
719
|
0.98 (0.84, 1.14)
|
0.75
|
0
|
0.84
| |
|
Days of Follow up
| | | | | | |
0.681
|
|
< 60
|
4
|
254
|
0.65 (0.30, 1.43)
|
0.29
|
74
|
0.009
| |
|
≥ 60
|
5
|
1382
|
0.99 (0.80, 1.23)
|
0.95
|
53
|
0.07
| |
|
Creatinine Difference
| | | | | | |
0.632
|
|
Significant
|
4
|
583
|
0.92 (0.55, 1.53)
|
0.74
|
67
|
0.03
| |
|
Nonsignificant
|
5
|
1053
|
1.02 (0.78, 1.33)
|
0.87
|
57
|
0.05
| |
|
UO Difference
| | | | | | |
0.079
|
|
Significant
|
2
|
259
|
0.40 (0.10, 1.63)
|
0.20
|
78
|
0.03
| |
|
Nonsignificant
|
5
|
1227
|
1.05 (0.92, 1.19)
|
0.48
|
0
|
0.42
| |
|
KDIGO
| | | | | | |
0.334
|
|
stage 1–2
|
5
|
627
|
0.74 (0.47, 1.17)
|
0.20
|
72
|
0.01
| |
|
stage 3
|
3
|
933
|
1.08 (0.84, 1.40)
|
0.54
|
31
|
0.23
| |
-
Abbreviations: RRT renal replacement therapy, EHV early high volume, ELV early low volume, LLV late low volume, CVVH continuous venovenous hemoflitration, IHD intermittent hemodialysis, UO urinary output, KDIGO kidney disease: improving global outcomes
